Kornimate/medical-research-clean huggingface dataset:
goal-directed therapy in neurosurgery.

Conditions: Surgery--Complications

Summary: the purpose of the study is to assess feasibility of future large randomised controled study aimed on assessment of effect of goal-directed therapy on incidence of complications in neurosurgery compared to standard care.

patients undergoing neurosurgical operations are at risk of inadequate intravascular volume for several reasons. the appropriate fluid management in neurosurgery is a challenge. goal-directed therapy has been shown to improve the outcome of patients undergoing major surgery. current knowledge regarding effect of fluid management on patient-orientated outcomes in neurosurgery is limited. this study is designed as a pilot study with two parallel groups. patients scheduled to planned brain surgery at the university hospital brno will be screened whether they meet the inclusion criteria. after obtaining informed consent, the patient will be randomized to one of the study arms. in one arm (standard) standard monitoring of vital signs will be introduced. during the operation, perioperative fluid therapy and administration of vasoactive agents will depend entirely at the discretion of the attending anaesthetist. postoperative therapy will be fully controlled and will depend on the decision of the attending physician. in the second arm (gdt), a non-invasive hemodynamic monitor starlink™sv will be introduced in addition to standard monitoring. in this arm, basal infusion with crystalloid balanced solution will be initiated. additional boluses of fluids will be administered based on haemodynamic monitoring. the primary outcome of the study is a proportion of patients with serious adverse event (sae). incidence of saes will be compared between study groups. sae will be defined as unsatisfactory brain tissue relaxation at the end of operation and any intervention for brain oedema postoperatively. the secondary outcome is to compare proportion of patients with postoperative complications in both groups and length of icu and hospital stay. this study will enroll 34 patients in total, 17 in each group. after completion of enrolment of patients the statistical analysis will be performed.

Eligibility criteria:
inclusion criteria: * age at least 18 years * anticipated duration of surgery at least 2 hours * signed written consent form * american society of anesthesiologists (asa) classification \< 4. exclusion criteria: * unavailability of hemodynamic monitor * emergency operation * asa ≥4 * sitting operating position and awake craniotomy * awake craniotomy * serious cardiorespiratory disorder * cardiac arrythmia * obesity with bmi above 35 kg/m2

Keywords: neurosurgery goal-directed therapy complications pilot study
dent disease mutation genotyping

Conditions: Dent Disease

Summary: this study will help the investigator determine whether certain genetic mutations, more than others, are a cause of more severe disease in dent disease.

during this study visit, the investigator will draw one tube, about two teaspoonfuls (1 to 1 ½ teaspoons for children), of blood from the subject's arm to obtain white blood cells. these white blood cells will be used as a source of dna for genetic testing. the investigator will use the isolated dna to try to identify the gene that is defective in dent disease by comparing it with the structure of genes in normal individuals, patients with dent disease, and family members for dent disease.

Eligibility criteria:
inclusion criteria: * the patient has been diagnosed, or in the process of being diagnosed with dent disease. * the patient has a family member diagnosed with dent disease. exclusion criteria: - none

Keywords: dent dents dent disease dent genetic testing clcn5 ocrl1 genetic testing for dent disease hereditary study for dent disease
a clinico-pathological study to investigate the possible infective causes of non-hodgkin lymphoma of the ocular adnexae

Conditions: Non-Hodgkin Lymphoma

Summary: patients with mucosa-associated lymphoid tissue (malt) lymphoma of the ocular adnexae (mloa) will be eligible for treatment with doxycycline (part a: clinico-pathological study); patients with other types of ocular lymphoma, inflammatory lesions or those ineligible/unwilling for treatment with doxycycline can participate in the only pathologic study (part b).

patients with suspected lymphoma of the ocular adnexae will undergo a diagnostic biopsy in the usual way. if lymphoma is confirmed the patient will undergo a full staging evaluation and entry into either part a or b of the study will then be considered as follows: * clinico-pathological (part a) for patients with malt lymphoma of the ocular adnexae (mloa) and eligible for treatment with doxycycline 100 mg twice daily for 3 weeks ; or * pathology only (part b) for patients with other types of ocular lymphoma, inflammatory lesions or those ineligible/unwilling for treatment with doxycycline.

Eligibility criteria:
inclusion criteria: 1. age 18 years or over 2. histologically confirmed marginal zone b-cell lymphoma of malt-type 3. lymphoma localised to the ocular adnexae (conjunctiva, lacrimal gland, orbit soft tissue, clinical stage iea) following a ct scan of neck, thorax, abdomen and pelvis, bone marrow aspirate/trephine, full blood count and biochemical profile 4. no previous treatment, excepting rt for localised lymphoma of the contralateral eye 5. at least one measurable lesion 6. no systemic antibiotic therapy in the last three months 7. no other malignancy in the previous 5 years apart from appropriately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix 8. in women with reproductive potential a willingness to use contraception from entry into the study for a period of 3 months 9. written informed consent exclusion criteria: 1. pregnant or lactating women 2. known allergy to tetracycline 3. patients unwilling to comply with the requirements of follow-up as defined by this protocol 4. myasthenia gravis (tetracycline can exacerbate muscle weakness) 5. systemic lupus erythematous (tetracycline can exacerbate the condition) 6. patients with large or rapidly enlarging tumours requiring immediate radiotherapy

Keywords: nhl of the ocular adnexae
validity and reliability of modified box and block test and targeted box and block test in patients with stroke

Conditions: Stroke

Summary: the aim of our study is investigated validity and reliabilty of modified box and block test and targeted box and block test in patients with stroke.

fifty patients with stroke will included in the study. box and block test, modified box and block test, targeted box and block test, 9 hole peg test, fugl-meyer assessment of the upper extremity will used to assess upper extremity. to evaluate validity between modified and targeted box and block tests and box and block test, 9 hole peg test, fugl-meyer assessment will used to correlation analysis tests. the investigator will evaluate after one week to test-retest reliability to patients. other pyhsiotherapist will evaluate to patients inter-rater reliability.

Eligibility criteria:
inclusion criteria: * diagnosed with stroke and in the chronic phase (having been diagnosed with stroke at least 6 months ago), * over 18 years old, * mini mental test score ≥ 24 points, * able to grasp and release a 2.5 cm cube on both upper extremities, * brunnstrom upper extremity staging ≥ 3 * modified ashworth scale ≤ 2, * able to sit independently in a chair for 2 minutes exclusion criteria: * having a neurological disease other than stroke * have had surgery in the last 6 months * severely affected upper extremity * uncooperative with physiotherapist * patients with neglect, aphasia and hemianopsia

Keywords: validity reliability modified box and block test targeted box and block test upper extremity
the geriatric acute & post-acute care coordination program for fall prevention in the emergency department ii

Conditions: Fall

Summary: in brief, this k76 study consists of a small open trial to refine the study protocol and train study personnel on study procedures (aim 1.b.). in aim 2, we will recruit older adults into a multidisciplinary fall prevention pilot study. participants will be randomly assigned to usual care with a traditional fall evaluation by an ed clinician (i.e., ed medical staff member) or an intervention. in the intervention, participants will receive an in-ed consultation by a physical therapist and pharmacist to determine reasons for the fall and offer additional education and training. participants will be provided an apple watch to record measures of fitness and falls, if possible, in the following 12 months. recurrent falls will be measured in twelve-month follow-up.

in order to determine whether a multifactorial fall prevention intervention is feasible, acceptable and may reduce recurrent falls in older adults presenting to the ed after a fall, we will randomize patients to usual care with a traditional fall evaluation by an ed clinician or an intervention. patients in the intervention arm receive a fall risk assessment and recommendations by a physical therapist. they are also evaluated by a pharmacist and participate in a medication therapy management session with the aim to reduce fall risk increasing medication.

Eligibility criteria:
inclusion criteria: * community-dwelling adult (non-institutionalized) 65 years-old or older presenting to ed after a fall * fall not due to syncope or external force (i.e., struck by car or assault) * fall not due to serious illness (i.e., stroke, acute myocardial infarction) * will be discharged to home/assisted living/rehabilitation at completion of ed visit (i.e., not admitted) * legally authorized representative able to give informed consent if patient has cognitive impairment on six item screener (score of less than four) either over the phone with witness present or in person * must screen or test negative for covid-19 exclusion criteria: * unable to give informed consent due to intoxication or altered mental status * presence of injuries that prevent mobilization (i.e., pelvic or lower extremity fractures) * allergies to any wearable device component * unable or unwilling to wear apple watch at home (only for periodic study visits) * patient has advanced cancer and/or is on hospice care * pts coming from snf or nursing home * previously enrolled in gapcare ii aim1.b

Keywords: prevention emergency department digital health apple watch physical therapy pharmacy gapcare geriatric
myocardial bridging in obstructive hypertrophic cardiomyopathy

Conditions: Myocardial Bridging; Obstructive Hypertrophic Cardiomyopathy; Atrial Fibrillation (AF)

Summary: this study investigated the impact of myocardial bridging (mb) and its characteristics on preoperative atrial fibrillation and survival in patients with obstructive hypertrophic cardiomyopathy (ohcm). we recruited 968 consecutive patients with ohcm who underwent myectomy at our institution between january 2015 and december 2019, including 144 patients with mb and 824 patients without mb. all patients received angiography before surgery. the diagnosis of preoperative atrial fibrillation was based on 12-lead electrocardiography, 24-hour holter electrocardiography, or in-hospital electrocardiogram monitoring, which was extracted from patients' medical records. surgical details and follow-up data were also collected.


Eligibility criteria:
inclusion criteria:i(i) age ≥ 18 years and (ii) diagnosis of ohcm based on clinical and echocardiographic evaluation. - exclusion criteria: (i) a history of heart surgery (ii) patients who had coronary atherosclerosis or myocardial infraction; (iii) patients who had no angiography records. -
preoperative oral nutritional supplement vs conventional dietary advice in major gastrointestinal surgery

Conditions: Surgery--Complications; Nutrition Aspect of Cancer

Summary: surgical outcome is associated the nutritional status of the patients. perioperative nutritional supplement for malnutritional patient were recommended. there are several guidelines were recommended the perioperative nutrition for malnutrition patients. but in our hospital, there are no consensus guideline applied for the clinical practice. the nutritional supplement was judged by only attending physical this study was conducted to comparing the perioperative nutritional supplement with oral supplement with conventional approach with only dietary advice alone for all patients who undergoing major gastrointestinal surgery.

the study design is a randomized controlled study. the eligible criteria is all patients who undergoing major gastrointestinal surgery including upper/lower gastrointestinal tract and hepatobiliary and pancratic surgery. after the informed consent are obtained. the patients are randomized into two group (study group and conventional group). the perioperative supplement with oral nutritional support and dietary advice were assigned in the study group. the conventional group were assigned only dietary advice. the blood test and nutritional assessment are performed by investigators in all participants. the participants were assessed two times before the operation (at first assigned and the day before the operation). the duration of nutritional supplement is at least fourteen days.the patient characteristic data, surgical intervention, and postoperative data were collected. the main outcome is the postoperative morbidity and mortality.

Eligibility criteria:
inclusion criteria: * age \> 18 year * undergoing major gastrointestinal surgery * able to take oral diet exclusion criteria: * unable to take oral diet * gastrointestinal tract insufficiency eg. gastrointestinal obstruction, perforation, malabsorption and peritonitis * allergy to milk * history of previous nutritional supplement from other source within one months * chronic kidney disease (egfr \< 60 ml/min/1.73 m2) * take preoperative supplement less than 14 days * refused or withdraw from the study
eradicate hp - treating helicobacter pylori with rhb-105

Conditions: Dyspepsia; Helicobacter Pylori Infection

Summary: the "test and treat" strategy for treating dyspeptic patients who are h. pylori positive is rapidly becoming the standard of care. this study will test the effectiveness of rhb-105, a new triple therapy to treat h. pylori infection in dyspeptic patients.

this is a, randomized, double-blind, placebo-controlled study of rhb-105 in adult subjects complaining of epigastric discomfort that have been screened and found to be positive for h. pylori infection via 13c urea breath test (ubt) and either fecal antigen test or clo test. eligible subjects will be randomized in a ratio of 1:2 between placebo arm (n=30) and the active arm (rhb-105) (n=60). subjects will receive study drug for 14 consecutive days. eradication of h. pylori infection will be determined based on 13c ubt conducted between 28 to 56 days after completion of study drug therapy. subjects will be unblinded upon 13c ubt analysis. this will provide timely active therapy to all subjects enrolled in this study. subjects in the placebo arm will be entitled to receive standard-of-care as prescribed by the treating physician following un-blinding. eradication failures (13c ubt-positive) in the active study drug arm will undergo upper endoscopy with sampling for culture and sensitivity testing (to rifabutin, amoxicillin, clarithromycin, and metronidazole). culture and sensitivity directed therapy as prescribed by the treating physician will be offered to these subjects.

Eligibility criteria:
inclusion criteria: 1. be ≥18 years of age and ≤ 65 years 2. have symptoms consistent with dyspepsia of at least two weeks duration (defined as recurrent pain or discomfort centered in the upper abdomen, often with a relation to meals) 3. be positive for h. pylori by 13c urea breath test (ubt) and also by fecal antigen test 4. be informed of the nature of the study and provide written informed consent before any study specific procedures are performed (or have a legally authorized representative sign consent) exclusion criteria: 1. have alarm symptoms/signs (including unexplained anemia \[iron deficiency), melena / hematemesis, anorexia, dysphagia, jaundice, weight loss) 2. have taken antibiotics in the 4 weeks prior to screening 3. have taken bismuth containing medications such as peptobismol in the 4 weeks prior to screening 4. have a history of any previous esophageal or gastric surgery, except for simple closure of perforated ulcer 5. have a history of gastric outlet obstruction 6. have a history of hypersecretory state such as zollinger-ellison syndrome 7. have a history of gastric cancer 8. have the presence of active gastric and duodenal ulcers or presence of 3 or more active ulcers

Keywords: helicobacter pylori h. pylori dyspepsia
comparison of seasonal allergic rhinitis treatment with 2 antihistamines used in combination with intranasal corticosteroid

Conditions: Seasonal Allergic Rhinitis

Summary: the purpose of this study is to compare the efficacy of olopatadine nasal spray with azelastine nasal spray when treatments are utilized in conjunction with fluticasone nasal spray for the treatment of seasonal allergic rhinitis.


Eligibility criteria:
inclusion criteria: * able to provide consent/assent * history of spring/summer allergic rhinitis * positive skin prick and/or intradermal test * absence of significant anatomic abnormalities, infection, bleeding, and mucosal ulcerations * non-pregnant (where applicable) * able to complete daily diary exclusion criteria: * smoker * concurrent disease such as rhinitis medicamentosa or large obstructive nasal polyps * history of current chronic sinusitis * asthma * use of anti-allergy immunotherapy, corticosteroids, chronic use of long acting antihistamines * history of severe, unstable, or uncontrolled cardiovascular, hepatic, renal and/or other diseases/illnesses * history or evidence of nasolacrimal drainage system malfunction

Keywords: rhinitis allergy nasal spray antihistamine intranasal corticosteroid
comparative efﬁcacy of rebamipide gargle and benzydamine hcl gargle in prevention and management of chemo- and radio-therapy-induced oral mucositis

Conditions: Oral Mucositis

Summary: evaluate preventive and therapeutic effects of rebamipide gargle on reducing incidence of oral mucositis in comparison with benzydamine hcl mouthwash.

oral mucositis is a common and potentially dangerous complication of anticancer treatment. inflammation and ulcerations of the oral mucosa make swallowing and, thereby, eating and drinking, difficult or even impossible, leading to anorexia and weight loss(araújo et al., 2018) .there is a serious risk of infections and even sepsis, particularly in immune-ompromised patients. om is associated with severe pain, affects the quality of life, and often requires reduction or suspension of chemotherapy and/or radiotherapy, thereby decreasing the relative dose intensity, which may worsen prognosis (shumsky et al., 2019). benzydamine hydrochloride is a widely used drug in dentistry , a non-steroidal anti-inflammatory drug, has shown topical anti-inflammatory, analgesic, anaesthetic and antimicrobial effects and is used to attenuate inflammatory conditions like radiation -induced oral mucositis or chemotherapy-induced oral mucositis (nithin, et al.,2018). in addition to this, benzydamine hcl is available on the egyptian market and its price is economical .rebamipide is a drug used for the treatment of gastritis and gastric ulcer. the mechanisms involved in the anti-ulcer and cytoprotective effects of rebamipide have been reported to include an effect on prostaglandin e2 synthesis via cox-2 expression (udagawaet al ., 2003), up-regulation of growth factors and their receptors such as egf and hgf ,induction of mucus secretion ,anti-free radical effects and inhibition of the production of inflammatory cytokines such as il-1, il-8, and tnf-α (yasuda et al., 2011). different treatment options and drugs have been tested in om, only some of which exhibited clinical relevance such as oral cryotherapy, keratinocyte growth factor and amino acids enriched diets. therefore, there is a clear requirement for new approaches to the prevention and effective treatment of om (mallick, benson, \& rath, 2016) in 2019 a meta-analysis performed by akagi and his colleagues (akagi et al., 2019) showed that gargling treatment with rebamipide is superior to placebo for the development of mucositis and stomatitis due to chemo-radio-therapy, especially for severe cases of grade 3 or higher. however, in order to confirm these trials, further well-designed analyses are needed, and evaluation of adverse events in observational studies are also required.

Eligibility criteria:
inclusion criteria:male and female patients with head and neck cancer and who will be prescribed radiotherapy at least 60 gy (roopashri et al., 2011). * patients who will sign an informed consent, * patients older than 18 years of age, * patients having normal renal and liver functions exclusion criteria:• . use of dentures, or having any source of infection in the mouth. * allergy to rebamipide or benzydamine hydrochloride(nithin et al., 2018) .
evaluating the effects of electroacupuncture and rosiglitazone combined therapy

Conditions: Type 2 Diabetes Mellitus With Features of Insulin Resistance

Summary: aims: to evaluate the efficacy of rosiglitazone (tzd) and electroacupuncture (ea) combined therapy on patients with type 2 diabetes mellitus (t2dm). a randomized single-blind placebo controlled clinical trial was used. methods: a total of 31 newly diagnostic type 2 diabetic patients, who fulfilled the eligibility criteria were recruited and received various allocated interventions. they were randomly assigned into two groups, the control group (tzd, n=15) and the experimental group (tzd + ea, n=16). changes in their plasma free fatty acid (ffa), glucose and insulin levels together with their homeostasis model assessment (homa) indices were statistically assessed between before and after treatment. hypoglycemic activity (%) was also compared between these two groups. expecting results: this study will compare the hypoglycemic activity and the ability of improving insulin resistance between the tzd and tzd+ea group. also, the lowering effect of the plasma ffa concentration will be investigated.

this study is compared the effect between combined therapy (ea+tzd) and drug (tzd) on the patient of type 2 dm.

Eligibility criteria:
inclusion criteria: * all included native taiwanese patients, age from 20 to 65 years who diagnosed with type 2 diabetes mellitus within 5 years and keep the same anti-hyperglycemic agents for control diabetes before and during the period in this study * compatible with the diagnostic criteria of diabetes mellitus according to american diabetes association exclusion criteria: * individuals with nephrotic syndrome (urine protein over 3.5 g/day) and edema or renal failure (serum creatinine over 115 μmol/l) * individuals who were diagnosed of heart failure (nyha fc iii\~iv) or pacemaker implantation * individuals with abnormal liver function (got and gpt level above 2 folds of normal range) or diagnosis of liver cirrhosis * individuals with higher hba1c level (hba1c above 9%) * pregnant women * individuals who were receiving the classes of drugs thiazolidinediones already * individuals who were receiving insulin therapy already * individuals who were receiving other therapy during the period of study * individuals suffering a homeostasis disorder or other systemic disease * individuals who did not comply with the treatment during the study period

Keywords: electroacupuncture rosiglitazone plasma glucose insulin resistance free fatty acid